Image source: Getty Images.
What: Shares of Biogen Inc. (NASDAQ: BIIB), a large neurology-focused biotechnology company, tumbled 15.7% last month, according to data from S&P Global Market Intelligence. Disappointing clinical results from a long shot new drug candidate was the main culprit.